Literature DB >> 12632532

Elevated serum values of procollagen III peptide (PIIIP) in patients with ulcerative colitis who will develop pseudopolyps.

Zarko Babic1, Vjekoslav Jagić, Zvonko Petrović, Ante Bilić, Kapetanović Dinko, Goranka Kubat, Rosana Troskot, Mira Vukelić.   

Abstract

AIM: To assess the impact of procollagen III peptide as a marker of collagenesis in the development of pseudopolyps in patients with ulcerative colitis.
METHODS: Development of pseudopolyps was monitored in 25 patients with ulcerative colitis classified according to Powell-Tuck index as mild (n=12) or moderate (n=13) form of disease. Patients with a mild form of disease were treated with oral mesalazine medication (2-4 g/day) and local mesalazine preparation (suppository). Patients with a moderate form of disease received oral mesalazine medication (2-4 g/day), local mesalazine preparation (suppository) and local methylprednisolone at an initial dose of 60 mg/day, followed by dose tapering. How many significant variables (previously determined by analysis of variance) were elevated in the groups with and without pseudopolyp developement was observed. ROC analysis for calculation of new index was made.
RESULTS: Serum values of procollagen III peptide (PIIIP), C-reactive protein (CRP) and C4 complement component (C4) were statistically significantly lower in the group of patients free from pseudopolyp development than those who developed one or more pseudopolyps (0.45+/-0.12 vs 1.42+/-0.70, P<0.0027; 7.6+/-4.7 vs 17.8+/-9.17, P<0.035; and 0.46+/-0.11 vs 0.34+/-0.16, P<0.068, respectively) at endoscopic conrtrols with patohistologically samples during 13 months. There were no statistically significant differences in the values of C3, ceruloplasmin and IgM between the two groups (P>0.05). Discrimination function analysis yielded highest standardized cannon coefficients for PIIIP (0.876), CRP (0.104), C3 (-0.534) and C4 (0.184) (P<0.036). The elevation in two of three laboratory variables (PIIIP, CRP and C4) reached sensitivity of 93 % and specificity of 90 % in the development of pseudopolyps.
CONCLUSION: It is proposed that an increase in two of the three laboratory parameters (PIIIP, CRP and C4) could improve the accuracy of prediction of the development of pseudopolyps. When using PIIIP, CRP and C4 on decision making, the positive predictive value and accuracy were 90 % and 92 %, respectively.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12632532      PMCID: PMC4621596          DOI: 10.3748/wjg.v9.i3.619

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease.

Authors:  A Stallmach; D Schuppan; H H Riese; H Matthes; E O Riecken
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

2.  Consistency in the terminology of colorectal dysplasia.

Authors:  R R Pascal
Journal:  Hum Pathol       Date:  1988-11       Impact factor: 3.466

3.  Serum aminoterminal propeptide of type III procollagen (S-PIIINP) and hepatobiliary dysfunction in patients with ulcerative colitis.

Authors:  M H Leidenius; L T Risteli; J P Risteli; E I Taskinen; I H Kellokumpu; K A Höckerstedt
Journal:  Scand J Clin Lab Invest       Date:  1997-07       Impact factor: 1.713

4.  [Indications for different collagen metabolism in Crohn disease and ulcerative colitis].

Authors:  H Matthes; A Stallmach; B Matthes; H Herbst; D Schuppan; E O Riecken
Journal:  Med Klin (Munich)       Date:  1993-04-15

Review 5.  Medical therapy of inflammatory bowel disease.

Authors:  P Rutgeerts
Journal:  Digestion       Date:  1998-08       Impact factor: 3.216

6.  Microalbuminuria in inflammatory bowel disease.

Authors:  N Mahmud; J Stinson; M A O'Connell; T J Mantle; P W Keeling; J Feely; D G Weir; D Kelleher
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

7.  Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

Authors:  T Sahmoud; G Hoctin-Boes; R Modigliani; A Bitoun; J F Colombel; J C Soule; C Florent; J P Gendre; E Lerebours; R Sylvester
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

8.  Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy.

Authors:  J Kjeldsen; O B Schaffalitzky de Muckadell; P Junker
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

9.  Elevated levels of plasma hyaluronan in septicaemia.

Authors:  S Berg; B Brodin; F Hesselvik; T C Laurent; R Maller
Journal:  Scand J Clin Lab Invest       Date:  1988-12       Impact factor: 1.713

10.  Cytokine production in pouchitis is similar to that in ulcerative colitis.

Authors:  R T Patel; I Bain; D Youngs; M R Keighley
Journal:  Dis Colon Rectum       Date:  1995-08       Impact factor: 4.585

View more
  2 in total

1.  Elevated serum procollagen type III peptide in splanchnic and peripheral circulation of patients with inflammatory bowel disease submitted to surgery.

Authors:  Matilde De Simone; Ugo Cioffi; Ettore Contessini-Avesani; Barbara Oreggia; Roberta Paliotti; Alberto Pierini; Gianni Bolla; Elide Oggiano; Stefano Ferrero; Fabio Magrini; Michele M Ciulla
Journal:  BMC Gastroenterol       Date:  2004-11-04       Impact factor: 3.067

Review 2.  Pseudopolyps in inflammatory bowel diseases: Have we learned enough?

Authors:  Dimitrios S Politis; Konstantinos H Katsanos; Epameinondas V Tsianos; Dimitrios K Christodoulou
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.